Dynamic model of SARS-CoV-2 spike protein reveals potential new vaccine targets

New model captures glycan molecules whose motions shield much of the spike protein from immune defenses

April 01, 2021

A key feature of SARS-CoV-2 is its spike protein, which extends from its surface and enables it to target and infect human cells. Extensive research has resulted in detailed static models of the spike protein, but these models do not capture the flexibility of the spike protein itself nor the movements of protective glycan chains of sugar molecules that coat it. A new, detailed model of the surface of the SARS-CoV-2 spike protein  by scientists from the Max Planck Institute of Biophysics in Frankfurt am Main, Germany, reveals previously unknown vulnerabilities that could inform development of vaccines.

In this visualization of antibody target sites, the SARS-CoV-2 spike protein is tethered to the viral membrane with a slender stalk. Patches of intense purple color at the surface of spike indicate potential target sites for antibodies that are not protected by the glycans chains of sugar molecules shown in green. These binding sites and their accessibility were identified with molecular dynamics simulations (MD) that capture the complete structure of the spike protein and its motions in a realistic environment.

To support vaccine development, Mateusz  Sikora and his colleagues aimed to identify novel potential target sites on the surface of the spike protein. To do so, they developed molecular dynamics simulations that capture the complete structure of the spike protein and its motions in a realistic environment.
 
These simulations show that glycans on the spike protein act as a dynamic shield that helps the virus evade the human immune system. Similar to car windshield wipers, the glycans cover nearly the entire spike surface by flopping back and forth, even though their coverage is minimal at any given instant.
 
By combining the dynamic spike protein simulations with bioinformatic analysis, the researchers identified spots on the surface of the spike proteins that are least protected by the glycan shields. Some of the detected sites have been identified in previous research, but some are novel. The vulnerability of many of these novel sites was confirmed by other research groups in subsequent lab experiments.
 
“We are in a phase of the pandemic driven by the emergence of new variants of SARS-CoV-2, with mutations concentrated in particular in the spike protein,” Sikora says. “Our approach can support the design of vaccines and therapeutic antibodies, especially when established methods struggle.” The method developed for this study could also be applied to identify potential vulnerabilities of other viral proteins.

Go to Editor View